Articles

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

Department of Hematology, UMC Utrecht Cancer Center, Utrecht, the Netherlands
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Rheumatology & Clinical Immunology, University of Groningen Medical Center, Groningen, the Netherlands
Department of Hematology, Oncology and Rheumatology, Heidelberg University, Amyloidosis Center, Heidelberg, Germany
Department of Haematology, Ghent University, Gent, Belgium
Department of Hematology, HagaZiekenhuis, Den Haag, the Netherlands
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium
Department of Hematology, Academic Medical Center, Lymphoma and Myeloma Center, Amsterdam, the Netherlands
Department of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
Department of Hematology, University of Groningen, Medical Center, Groningen, the Netherlands
Department of Hematology, VU University Medical Center, Amsterdam Cancer Center, Amsterdam, the Netherlands
Department of Internal Medicine, Maxima Medisch Centrum, Eindhoven, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, St. Antonius Hospital, Nieuwegein, the Netherlands
Department of Hematology, Maastricht University Medical Center, Maastricht, the Netherlands
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Hematology, Oncology and Rheumatology, Heidelberg University, Amyloidosis Center, Heidelberg, Germany
Vol. 104 No. 11 (2019): November, 2019 https://doi.org/10.3324/haematol.2018.213900